Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Metadata referenced Merck & Co., Inc., but the filing text is for Schering-Plough).
Reporting Period: Fiscal year ended December 31, 2004.
Overview: Schering-Plough is a global science-based health care company operating in Prescription Pharmaceuticals, Consumer Health Care, and Animal Health segments. The company is in a turnaround phase under a new management team (appointed April 2003) implementing an "Action Agenda" to stabilize and repair operations following significant negative events, including an FDA consent decree regarding manufacturing practices and the loss of marketing exclusivity for key products like CLARITIN and REBETOL.
Key Financial Metrics (2004)
| Metric | 2004 Value | 2003 Value |
|---|---|---|
| Net Sales | $8,272 million | $8,334 million |
| Net Loss | $(947) million | $(92) million |
| Loss per Share (Diluted) | $(0.67) | $(0.06) |
| Operating Cash Flow | $(154) million (Used) | $601 million (Provided) |
| Long-Term Debt | $2,392 million | $2,410 million |
| Total Assets | $15,911 million | $15,271 million |
| Shareholders' Equity | $7,556 million | $7,337 million |
Margins: Cost of sales was 37.1% of net sales (up from 34.0% in 2003). Selling, general, and administrative (SG&A) expenses were 46.1% of net sales (up from 41.7% in 2003). Research and development (R&D) expenses were 19.4% of net sales.
Material Changes vs. Prior Period
- Profitability: The company reported a net loss of $947 million in 2004, a significant deterioration from the $92 million loss in 2003. This was driven by a $779 million tax expense (primarily related to the repatriation of foreign earnings) and increased operating costs.
- Revenue: Consolidated net sales decreased slightly by 1% ($62 million) compared to 2003. This was due to volume declines offset by a favorable foreign exchange impact of 4%.
- Segment Performance:
- Prescription Pharmaceuticals: Sales declined 3% to $6.417 billion. Profit collapsed to $13 million from $513 million in 2003, heavily impacted by special charges and declining sales of key products like PEG-INTRON and REBETOL.
- Consumer Health Care: Sales increased 6% to $1.085 billion, driven by foot care and sun care growth, though OTC CLARITIN sales declined.
- Animal Health: Sales increased 10% to $770 million.
- Special Charges: Total special charges were $153 million in 2004, down significantly from $599 million in 2003. The 2004 charges included $119 million in employee termination costs and $34 million in asset impairments. The 2003 charges were dominated by a $350 million litigation reserve increase.
- Equity Income: Equity income from the cholesterol joint venture with Merck (ZETIA/VYTORIN) increased to $347 million from $54 million in 2003, reflecting the launch of VYTORIN in the U.S.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Management expects 2005 worldwide dividends and capital expenditures to exceed cash generated from operations. U.S. operations are expected to continue generating negative cash flow.
- The company intends to repatriate approximately $9.4 billion of foreign earnings in 2005 under the American Jobs Creation Act of 2004 to fund U.S. cash needs and stabilize financial resources.
- Future profitability is heavily dependent on the success of the cholesterol franchise (ZETIA/VYTORIN) and the ability to control expenses.
Key Risks and Contingencies:
- Legal Investigations: The company is a target of a federal criminal investigation by the U.S. Attorney's Office for the District of Massachusetts regarding sales and marketing practices. A liability of approximately $250 million has been recorded, but a settlement could materially exceed this amount. A separate investigation in Pennsylvania was settled in 2004 for approximately $292 million.
- Regulatory Compliance: The company is subject to an FDA consent decree regarding manufacturing practices. Failure to meet deadlines could result in additional payments and production halts.
- Product Competition: Significant sales declines in the hepatitis C franchise (PEG-INTRON/REBETOL) due to generic competition and new branded entrants. The switch of CLARITIN to OTC status has resulted in lower average selling prices and intense competition.
- Credit Ratings: Credit rating agencies (Moody's, S&P, Fitch) have downgraded the company's debt ratings to investment grade levels (e.g., Baa1, A-) with negative outlooks, increasing borrowing costs and potentially restricting commercial paper access.
Investor Verification Checklist
- Massachusetts Investigation Status: Verify the current status of the federal criminal investigation and whether the $250 million accrual remains sufficient or if additional reserves are needed.
- FDA Consent Decree Progress: Confirm the company's progress on revalidation programs and cGMP work plans to avoid further penalties or production stoppages.
- Cholesterol Joint Venture Performance: Monitor sales growth and market share of ZETIA and VYTORIN, as these are critical to the company's turnaround strategy.
- Cash Flow Sustainability: Assess the timeline for the repatriation of foreign earnings and the company's ability to fund U.S. operations without further equity or debt issuance.
- Product Pipeline: Evaluate the status of new product approvals (e.g., garenoxacin) and the impact of the Bayer alliance on future revenue streams.